Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose methylprednisolone vs intermediate-dose dexamethasone for non-critical COVID-19 respiratory failure
2020-005026-28Phase 4Completed
- Sponsor
- Hospital Universitario de Salamanca
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Intermediate-dose dexamethasone with High-dose methylprednisolone bolus (2 arms). Primary endpoint: Death. Started Nov 2020; status: completed.
02
Drugs
dexamethasonemethylprednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005026-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005026-28.